Abstract
Medullary thyroid cancer (MTC) is a neuroendocrine malignancy, which originates from C cells (parafollicular) of the gland. MTC is inherited in autosomal dominant pattern in 20–25% of patients with MEN syndromes. Familial MTC (FMTC) is the most frequent type of MEN syndromes.
The most accepted approach for deciding surgical treatment of the disease based on the precise polymer mutation within the douse factor occurring within the family and blood serum calcitonin levels.
RET mutations may be classified as highest, high, and moderate risk, concerning the potential risk for native and distant MTC metastases at an early age. The advised temporal order of excision relies upon proof of age-dependent and codon-specific progression of early MTC.
In conclusion, patients with inherited MTC ought to experience age-suitable thyroidectomy in view of RET mutational status to evade recurrences.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Cancer of the Thyroid Invasive: Trends in SEER Incidence and U.S. Mortality Using the Joinpoint Regression Program, 1975–2011(SEER) Stat version 8.1.2 Rate Session. Access the SEER 18 database at www.seer.cancer.gov). Incidence - SEER 18 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov 2012 Sub (2000–2010) - Linked To County Attributes - Total U.S., 1969–2011 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2013, based on the November 2012 submission.
Hadoux J, Pacini F, Tuttle RM, Schlumberger M. Management of advanced medullary thyroid cancer. Lancet Diabetes Endocrinol. 2016;4:64–71.
Leboulleux S, Baudin E, Travagli J, Schlumberger M. Medullary thyroid carcinoma. Clin Endocrinol. 2004;61:299–310.
Wells S, Asa S, Dralle H, Elisei R, Evans D, Gagel R, et al. Revised American Thyroid Association guidelines for the Management of Medullary Thyroid Carcinoma. Thyroid. 2015;25:567–610.
Bockhorn M, Frilling A, Rewerk S, Liedke M, Dirsch O, Schmid K, et al. Lack of elevated serum Carcinoembryonic antigen and calcitonin in medullary thyroid carcinoma. Thyroid. 2004;14:468–70.
Redding A, Levine S, Fowler M. Normal preoperative calcitonin levels do not always exclude medullary thyroid carcinoma in patients with large palpable thyroid masses. Thyroid. 2000;10:919–22.
Diez JJ, Iglesias P. Lack of elevated serum carcinoembryonic antigen and calcitonin in medullary thyroid carcinoma. Thyroid. 2004;14:984–5.
Heshmati HM, Hofbauer LC. Multiple endocrine neoplasia type 2: recent progress in diagnosis and management. Eur J Endocrinol. 1997;137:572–8.
Schilling T, Burck J, Sinn HP, Clemens A, Otto HF, Hoppner W, et al. Prognostic value of codon 918 (ATG-->ACG) RET proto-oncogene mutations in sporadic medullary thyroid carcinoma. Int J Cancer. 2001;95:62–6.
Elisei R, Cosci B, Romei C, Bottici V, Renzini G, Molinaro E, et al. Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. J Clin Endocrinol Metab. 2008;93:682–7.
Raue F, Frank-Raue K. Genotype-phenotype correlation in multiple endocrine neoplasia type 2. Clinics (Sao Paulo). 2012;67(Suppl 1):69–75.
Imai T, Uchino S, Okamoto T, Suzuki S, Kosugi S, Kikumori T, et al. High penetrance of pheochromocytoma in multiple endocrine neoplasia 2 caused by germ line RET codon 634 mutation in Japanese patients. Eur J Endocrinol. 2013;168:683–7.
Jasim S, Ying AK, Waguespack SG, Rich TA, Grubbs EG, Jimenez C, et al. Multiple endocrine neoplasia type 2B with a RET proto-oncogene A883F mutation displays a more indolent form of medullary thyroid carcinoma compared with a RET M918T mutation. Thyroid. 2011;21:189–92.
Frank-Raue K, Rybicki LA, Erlic Z, Schweizer H, Winter A, Milos I, et al. Risk profiles and penetrance estimations in multiple endocrine neoplasia type 2A caused by germline RET mutations located in exon 10. Hum Mutat. 2011;32:51–8.
Cuccuru G, Lanzi C, Cassinelli G, Pratesi G, Tortoreto M, Petrangolini G, et al. Cellular effects and antitumor activity of RET inhibitor RPI-1 on MEN2A-associated medullary thyroid carcinoma. J Natl Cancer Inst. 2004;96:1006–14.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Sezer, A., Çelik, M. (2019). Prophylactic and Therapeutic Surgery in Familial Medullary Thyroid Cancer. In: Özülker, T., Adaş, M., Günay, S. (eds) Thyroid and Parathyroid Diseases. Springer, Cham. https://doi.org/10.1007/978-3-319-78476-2_59
Download citation
DOI: https://doi.org/10.1007/978-3-319-78476-2_59
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-78475-5
Online ISBN: 978-3-319-78476-2
eBook Packages: MedicineMedicine (R0)